布比卡因脂质体与标准关节周围注射在全膝关节置换术联合区域麻醉中的比较:一项前瞻性随机对照试验
这项前瞻性、随机、单盲对照试验比较了布比卡因脂质体(Exparel)关节周围注射与含常规布比卡因的标准关节周围注射在区域麻醉下全膝关节置换术中的效果。共纳入59例患者,主要结局为达到出院回家目标所需的物理治疗次数,两组无统计学显著差异(3.0±1.2 vs 3.6±1.3,P=.137),临床次要结局亦无显著差异,但药物费用存在显著差异。
要点
- 布比卡因脂质体与标准布比卡因关节周围注射在全膝关节置换术中临床结局无显著差异。
- 主要结局物理治疗次数分别为3.0±1.2与3.6±1.3,P=.137。
- 药物费用存在显著差异。
核心结论
- 研究支持先前文献,即布比卡因脂质体相比标准治疗在全膝关节置换术中无显著临床获益,并强调该药物的费用担忧。
研究设计与样本
- 前瞻性、随机、单盲、对照试验,比较布比卡因脂质体关节周围注射与含常规布比卡因的标准关节周围注射,在区域麻醉 setting 下进行。
- 所有协作外科医生的成人单侧全膝关节置换术患者均符合参与资格,按1:1随机分配至布比卡因脂质体方案或标准治疗案。
- 根据先验功效计算,在1例因随机化错误排除后,共纳入59例患者。
主要发现
- 两组人口学特征无显著差异。
- 达到出院回家目标所需物理治疗次数的主要结局无统计学显著差异(3.0±1.2 vs 3.6±1.3,P=.137)。
- 临床次要结局亦无统计学显著差异。
- 药物费用存在显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liposomal bupivacaine (Exparel) is a long-acting local anesthetic preparation with demonstrated efficacy over placebo in reducing postoperative pain and opioid requirement. Limited comparative efficacy and cost-effectiveness data exist for its use in total knee arthroplasty (TKA) when used in a multimodal, opioid-sparing analgesic and anesthetic approach. We hypothesized that liposomal bupivacaine offers no clinical advantage over our standard of care but carries significant economic impact. METHODS: This is a prospective, randomized, single-blinded, controlled trial comparing liposomal bupivacaine periarticular injection (PAI) to our current approach including conventional bupivacaine PAI, in the setting of regional anesthesia. All adult unilateral TKA patients of the collaborating surgeon were eligible to participate in the study. Patients were randomized 1:1 to either the liposomal bupivacaine protocol or the standard-of-care protocol. All patients received regional anesthesia and standard postoperative analgesia protocols. Patients and all postoperative healthcare providers were blinded to study arm assignment. RESULTS: A total of 59 patients were enrolled per our a priori power calculation after 1 exclusion for randomization error. No significant demographic differences between the study arms were found. There was no statistically significant difference in the primary outcome of number of physical therapy (PT) sessions required to achieve home-going discharge goals (3.0 ± 1.2 vs 3.6 ± 1.3, P = .137), nor in the clinical secondary outcomes. A significant difference in medication charges was found. CONCLUSION: Our study supports earlier literature suggesting no significant clinical benefit of using liposomal bupivacaine over standard of care in TKA and underscores cost-of-care concerns with this agent.
引用
- Hyland SJ, Deliberato DG, Fada RA, et al. Liposomal Bupivacaine Versus Standard Periarticular Injection in Total Knee Arthroplasty With Regional Anesthesia: A Prospective Randomized Controlled Trial. J Arthroplasty. 2018. PMID: 30554925. doi:10.1016/j.arth.2018.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。